Germany-based biopharmaceutical company ATAI Life Sciences announced its decision to allocate a portion of its treasury reserves to BTC, following in the footsteps of firms that have embraced Bitcoin as a strategic asset.
ATAI Life Sciences Chairman Christian Angermayer referred to the potential role of Bitcoin in capital preservation and optimization, explaining this move in a Substack post:
“In an era of persistent inflation and volatile markets, I find myself asking an important question for biotechnology companies that want to preserve and optimize their capital: Could allocating a portion of treasury cash to Bitcoin help a company preserve its capital, optimize it, and even extend its maturity, thereby contributing to its success?”
As part of its Bitcoin treasury strategy, ATAI Life Sciences will make an initial investment of 5 million dollars in BTC while maintaining sufficient cash reserves, short-term securities, and public equity to cover operational expenses until 2027.
The company’s decision aligns with a growing trend among companies looking to diversify their treasury assets by including Bitcoin. This approach was popularized by MicroStrategy, where co-founder and CEO Michael Saylor is a vocal advocate for the adoption of institutional Bitcoin.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
